In the future, molecular imaging techniques are likely to play a role in the management of prostate cancer at all stages of the disease, from the use of hyperpolarised MR in organ-confined disease, to the use of choline or PSMA tracers to detect early recurrence, right through to the detection of distant disease with NaF and FDG-PET. The gene discussed is FOLH1; the disease is prostate cancer.